laninamivir

thumb|Inavir Laninamivir (CS-8958) is a neuraminidase inhibitor that is a drug used for the treatment and prophylaxis of Influenzavirus A and Influenzavirus B. It is currently in Phase III clinical trials. It is a long-acting neuraminidase inhibitor administered by inhalation.

Chemical data

Formula: C13H22N4O7
Molecular weight: 346.34 g/mol
IUPAC name: (2R,3R,4S)-3-acetamido-4-(diaminomethylideneamino)-2-[(1R,2R)-2,3-dihydroxy-1-methoxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid
SMILES: CC(=O)N[C@@H]1[C@H](C=C(O[C@H]1[C@@H]([C@@H](CO)O)OC)C(=O)O)N=C(N)N
InChIKey: QNRRHYPPQFELSF-CNYIRLTGSA-N
XLogP: -3.2
Polar surface area: 190 Å²
H-bond donors: 6
H-bond acceptors: 8
Formal charge: 0

via PubChem

Drug data · ChEMBL

Max clinical phase: Phase 2
Molecule type: Small molecule
Indications: viral disease, influenza

via ChEMBL · EBI

Wikidata facts

Subclass of: chemical compound
Mass: 346.149

Show 4 more facts

chemical formula: C₁₃H₂₂N₄O₇
canonical SMILES: CC(=O)NC1C(C=C(OC1C(C(CO)O)OC)C(=O)O)N=C(N)N
isomeric SMILES: CC(=O)N[C@@H]1[C@H](C=C(O[C@H]1[C@@H]([C@@H](CO)O)OC)C(=O)O)N=C(N)N
Commons category: Laninamivir

Sources (2)

via Wikidata · CC0

~1 min read

Encyclopedic overview

1 sections

Contents

References

Laninamivir was approved for influenza treatment in Japan in 2010 and for prophylaxis in 2013. It is currently marketed under the name Inavir by Daiichi Sankyo. Biota Pharmaceuticals and Daiichi Sankyo co-own Laninamivir. On 1 April 2011, BARDA awarded up to an estimated U$231m to Biota Pharmaceuticals (Formerly Biota Holdings Ltd) wholly owned subsidiary, Biota Scientific Management Pty Ltd, for the advanced development of Laninamivir in the US. It is under clinical evaluations in other countries.

Excerpted from Wikipedia’s “laninamivir” article, available under the CC BY-SA 4.0 licence.

Gallery (2)

Available in 11 languages

via Wikidata sitelinks · CC0